Board Appointment

 

TIDMAZM 
 
RNS Number : 2622P 
Alizyme PLC 
23 March 2009 
 

 
 
+----------------------------------------+-------------------------------------+ 
| For immediate release                  |                       23 March 2009 | 
+----------------------------------------+-------------------------------------+ 
 
 
 
 
ALIZYME PLC 
 
 
BOARD APPOINTMENTS AND RESIGNATION 
 
 
Cambridge UK, 23 March 2009: Alizyme plc (LSE:AZM) announces the appointments of 
Dr Roger Lloyd and Mr Richard de Souza as Non-Executive Directors with effect 
from 1 April 2009 and the resignation of Mr William Edge as a Non-Executive 
Director with effect from 1 April 2009. 
 
 
Dr Lloyd, aged 60, is a senior biotechnology and healthcare industry 
professional with over 33 years' experience working for ICI, Zeneca and 
AstraZeneca. Originally trained as a biochemist, his business development 
experience has been extensive. Numerous international transactions have included 
corporate acquisitions, product and technology licensing, joint ventures, 
divestments, corporate merger and demerger. His international experience has 
included living and working in the United States and Germany, and having 
territorial responsibilities for Europe, Japan, Korea, Mexico and the Middle 
East. He recently retired as Executive Director, Global Licensing in AstraZeneca 
plc and is currently a non-executive director of Epistem Holdings plc. Dr Lloyd 
will join the Board with effect from 1 April 2009. There are no other 
disclosures relating to Dr Lloyd under Listing Rule LR 9.6.13. 
 
 
Mr de Souza, aged 56, is a pharmacist who started his career at SmithKline 
Beecham in manufacturing before moving through business development and 
marketing roles into general management. Through his earlier career, he has been 
Managing Director, then Regional Director, living in six countries worldwide and 
has served as the Area Director with overall responsibility in Marketing and 
Business Development for Europe, USA and international markets during his 
twenty-two years with SmithKline Beecham. He served as Chairman Europe for 
SmithKline Beecham and then President Europe and International for Warner 
Lambert. Latterly at Shire, he was Director International, responsible for 
Pharmaceuticals outside the US and Biologicals and Diagnostics globally. In 2004 
he set up Archimedes Pharma Ltd, a European specialty pharmaceutical company, 
where he is Chairman and CEO. Mr de Souza will join the Board with effect from 1 
April 2009. There are no other disclosures relating to Mr de Souza under Listing 
Rule LR 9.6.13. 
 
 
Mr  Edge, who has served as a Non-Executive Director since 1998, will retire 
from the Board with effect from 1 April 2009. 
 
 
Sir Brian Richards (Chairman) commented: 
 
 
"I am delighted to welcome Roger Lloyd and Richard de Souza to the Board. I 
believe they will provide invaluable advice and guidance in enabling Alizyme to 
pursue its strategy and achieve its objectives of becoming a profitable, 
self-sustaining biopharmaceutical product development company. 
 
 
I would like to thank Bill for his many years of support and advice to Alizyme." 
 
 
 
 
For further information, please contact: 
 
 
+------------------------------------+---------------------------------+ 
| ALIZYME PLC                        |      Tel: + 44 (0) 1223 896000  | 
| Tim McCarthy, Chief Executive      |                                 | 
| Officer                            |                                 | 
|                                    |                                 | 
+------------------------------------+---------------------------------+ 
| BUCHANAN COMMUNICATIONS            |     Tel: + 44 (0) 20 7466 5000  | 
| Lisa Baderoon                      |       Tel: + 44 (0) 7721 413496 | 
| Rebecca Skye Dietrich              |                                 | 
+------------------------------------+---------------------------------+ 
 
 
Further information on Alizyme can be found on the Company's website: 
www.alizyme.com 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 BOAPUUBPWUPBGBP